- Home
- CELZ vs VCNX Comparison
CELZ vs VCNX Comparison
Compare CELZ & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- VCNX
- Stock Information
- Founded
- CELZ 1998
- VCNX 2001
- Country
- CELZ United States
- VCNX United States
- Employees
- CELZ N/A
- VCNX N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- VCNX Health Care
- Exchange
- CELZ Nasdaq
- VCNX Nasdaq
- Market Cap
- CELZ 4.7M
- VCNX 4.5M
- IPO Year
- CELZ N/A
- VCNX N/A
- Fundamental
- Price
- CELZ $2.55
- VCNX $3.63
- Analyst Decision
- CELZ
- VCNX
- Analyst Count
- CELZ 0
- VCNX 0
- Target Price
- CELZ N/A
- VCNX N/A
- AVG Volume (30 Days)
- CELZ 62.2K
- VCNX 115.4K
- Earning Date
- CELZ 11-08-2024
- VCNX 11-14-2024
- Dividend Yield
- CELZ N/A
- VCNX N/A
- EPS Growth
- CELZ N/A
- VCNX N/A
- EPS
- CELZ N/A
- VCNX N/A
- Revenue
- CELZ $11,000.00
- VCNX $388,000.00
- Revenue This Year
- CELZ N/A
- VCNX N/A
- Revenue Next Year
- CELZ N/A
- VCNX N/A
- P/E Ratio
- CELZ N/A
- VCNX N/A
- Revenue Growth
- CELZ N/A
- VCNX N/A
- 52 Week Low
- CELZ $2.41
- VCNX $1.39
- 52 Week High
- CELZ $10.28
- VCNX $13.02
- Technical
- Relative Strength Index (RSI)
- CELZ 36.30
- VCNX 55.50
- Support Level
- CELZ $2.41
- VCNX $3.04
- Resistance Level
- CELZ $2.67
- VCNX $3.95
- Average True Range (ATR)
- CELZ 0.29
- VCNX 0.38
- MACD
- CELZ -0.05
- VCNX 0.05
- Stochastic Oscillator
- CELZ 11.21
- VCNX 70.37
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.